Brief: Histogen Receives Us FDA Ind Approval To Initiate Phase 1B/2A Trial Of Hst 001 In Androgenic Alopecia
11/05/2020 13:53
Conatus Pharmaceuticals Inc CNAT.O :
* HISTOGEN RECEIVES US FDA IND APPROVAL TO INITIATE PHASE
1B/2A
TRIAL OF HST 001 IN ANDROGENIC ALOPECIA
* HISTOGEN - INTENDS TO INITIATE A PHASE 1B/2A CLINICAL
TRIAL OF
HST 001 IN Q2
Source text for Eikon: ID:nGNX55tjsP
Further company coverage: CNAT.O
Recent news on Histogen
See all newsBrief: Histogen Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Histogen Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Histogen Announces Board Approval Of Complete Liquidation And Dissolution
Histogen Inc expected to post a loss of 90 cents a share - Earnings Preview
Histogen to explore strategic options, shares up